Next Article in Journal
Publisher’s Note: A New Chapter for Hematology Reports—Continued Publication by MDPI
Previous Article in Journal
Lysine-Specific Histone Demethylase 1 Inhibition Enhances Robust Fetal Hemoglobin Induction in Human β0-Thalassemia/Hemoglobin E Rrythroid Cells
 
 
Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Direct Oral Anticoagulants: A Review for the Non-Specialist

by
Thilina Gunawardena
Department of Vascular and Transplant Surgery, National Hospital of Sri Lanka, Colombo 00700, Sri Lanka
Hematol. Rep. 2021, 13(4), 9239; https://doi.org/10.4081/hr.2021.9239
Submission received: 30 April 2021 / Revised: 25 August 2021 / Accepted: 2 September 2021 / Published: 26 November 2021

Abstract

Thrombin inhibitors and direct factor Xa inhibitors represent a major breakthrough in the field of anticoagulation pharmacotherapy. These novel agents have replaced warfarin as the oral anticoagulant of choice in certain indications, as they possess equal or superior efficacy and better safety profiles. They have a quick onset of action, predictable pharmacokinetic properties and minimal drug and food interactions. So they do not require frequent blood monitoring and dose adjustments as with warfarin. Considering all the advantages, there seems to be a rapid increase in the number of patients who are started on these novel anticoagulants. In this review, we highlight the pharmacology of these direct oral anticoagulants and the evidence-based indications for their use. We aim to provide a clinical overview for the non-specialist who may be called upon to manage a patient who is currently on one of these novel anticoagulants.
Keywords: DOAC; dabigatran; rivaroxaban; apixaban; edoxaban; oral anticoagulants DOAC; dabigatran; rivaroxaban; apixaban; edoxaban; oral anticoagulants

Share and Cite

MDPI and ACS Style

Gunawardena, T. Direct Oral Anticoagulants: A Review for the Non-Specialist. Hematol. Rep. 2021, 13, 9239. https://doi.org/10.4081/hr.2021.9239

AMA Style

Gunawardena T. Direct Oral Anticoagulants: A Review for the Non-Specialist. Hematology Reports. 2021; 13(4):9239. https://doi.org/10.4081/hr.2021.9239

Chicago/Turabian Style

Gunawardena, Thilina. 2021. "Direct Oral Anticoagulants: A Review for the Non-Specialist" Hematology Reports 13, no. 4: 9239. https://doi.org/10.4081/hr.2021.9239

APA Style

Gunawardena, T. (2021). Direct Oral Anticoagulants: A Review for the Non-Specialist. Hematology Reports, 13(4), 9239. https://doi.org/10.4081/hr.2021.9239

Article Metrics

Back to TopTop